The past decade has seen great advances in the management of patients with
HIV infection. The introduction of highly active antiretroviral therapy (HA
ART) has resulted in a decrease in opportunistic infections but the develop
ment of new clinical entities such as lipodystrophy and immune reconstituti
on illnesses. The use of investigations such as lipid profiles and dual ene
rgy X-ray absorptiometry (DEXA) scanning to assess lipodystrophy have been
necessitated by these changes in the epidemic. Technological advances have
resulted in new techniques such as viral resistance assays and single photo
n emission computed tomography (SPECT) scanning. The appropriate use of the
se investigations is subject to ongoing assessment.